Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Relapsed or Refractory High Grade Glioma (HGG)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2017
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Glioma
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 26 Sep 2017 Planned End Date changed from 23 Aug 2024 to 9 Sep 2024.
- 26 Sep 2017 Planned initiation date changed from 30 Oct 2017 to 15 Nov 2017.
- 05 Jul 2017 Planned End Date changed from 13 Apr 2022 to 23 Aug 2024.